Factor V Leiden is not a bleeding disorder like hemophilia, nor is it a blood disease in the sense of anemia or a clotting factor deficiency. Instead, it is an inherited thrombophilia—a hypercoagulable clotting disorder where blood clots more easily and faster than normal because a specific clotting factor breaks down far slower than it should. The vast majority of people with this genetic variant never develop a blood clot.
What Is the Factor 5 Leiden Mutation?
In normal coagulation, an anticoagulant protein called activated protein C (APC) inactivates coagulation factor V by cleaving it at a specific site at position Arg534 (historically designated Arg506). Factor V Leiden is a point mutation (c.1601G>A or G1691A, rs6025) in the F5 gene located on chromosome 1 that destroys this APC cleavage site.
Because of this mutation, activated protein C inactivates factor V roughly ten times slower than normal. As a result, clotting activity remains active longer, increasing the tendency to form venous blood clots.
The underlying APC resistance was discovered in the late 1980s in the laboratory of Björn Dahlbäck in Malmö, Sweden. In 1994, Rogier Maria Bertina in the laboratory of Pieter Hendrik Reitsma at Leiden University in the Netherlands identified the specific point mutation in the factor V gene. The original 1994 publication in Nature identified the mutation in 56 of 64 APC-resistant thrombosis patients from a cohort of 301 consecutive patients. The allele frequency in the Dutch population was around 2%—at least ten times higher than all previously known genetic thrombosis risk factors combined. The condition was named after the city of Leiden, where Bertina’s team identified the defect.
Inheritance and Numbers: Heterozygous vs. Homozygous
Factor V Leiden is inherited in an autosomal dominant pattern with incomplete penetrance, meaning that carrying the mutation does not guarantee a person will develop a thrombosis. The mutation is not sex-linked and affects men and women equally.
Inheritance risks depend on parental genetics: if one parent is heterozygous, each child has a 50% chance of inheriting the mutated allele. If both parents are heterozygous, each child has a 25% chance of homozygosity, a 50% chance of heterozygosity, and a 25% chance of wild type. If one parent is homozygous, all children inherit at least one copy of the mutation (100% heterozygous).
| Genetic Status | Copies Inherited | Estimated Prevalence | Relative Clot Risk | Annual Clot Risk |
|---|---|---|---|---|
| Non-Carrier (Wild Type) | 0 | General population | Baseline (1x) | ~1 per 1,000 (~0.1%) |
| Heterozygous Factor V Leiden | 1 (from one parent) | ~5.2% of European Americans | 5- to 7-fold increase | 3 to 8 per 1,000 (0.3%–0.8%) |
| Homozygous Factor V Leiden | 2 (from both parents) | Rare (~1 in 5,000 / 0.02%) | 20- to 80-fold increase | Up to 80 per 1,000 (~8%) |
Prevalence varies among ethnic groups in the United States: roughly 5.2% of European Americans, 2.2% of Hispanic Americans, 1.25% of Indigenous Americans, 1.2% of African Americans, and 0.45% of Asian Americans carry the mutation. It is most common in Northern Europeans and certain Middle Eastern populations. Overall, 15% to 20% of people with a first deep vein thrombosis (DVT) carry the factor V Leiden mutation, rising to up to 50% in cases of recurrent or estrogen-associated DVT. The lifetime risk of DVT for heterozygous carriers is approximately 10% or lower, though it may be higher with a positive family history. Approximately 5% of the general population and up to 20% of individuals from thrombophilic families with factor V Leiden ever develop a clot.
Recognizing Symptoms and Emergency Warning Signs
The genetic mutation itself produces no symptoms. The first indication of the condition is often a deep vein thrombosis or a pulmonary embolism.
Recognized signs of thrombotic events include:
- Deep Vein Thrombosis (DVT) in the leg: Can occur without symptoms. When present, signs include swelling, pain, warmth, and skin discoloration (redness, which may be harder to detect on darker skin tones).
- Pulmonary Embolism (PE): Sudden shortness of breath, sharp chest pain when inhaling, and coughing up blood.
- Internal Jugular Vein Thrombosis (Neck Clot): Pain along the side of the neck, localized swelling near the angle of the jaw, a sensation of pressure, a palpable cord-like vein running beneath the sternocleidomastoid muscle, and often headache.
- Cerebral Venous Sinus Thrombosis: Typically presents with severe headache (often described as the worst headache ever experienced), visual disturbances, focal deficits, seizures, or altered consciousness.
Under the “Factor V Leiden paradox,” patients with factor V Leiden present with isolated pulmonary embolism without an identifiable DVT less frequently than the general thrombosis population. Potential complications of venous thromboembolism include post-thrombotic syndrome (chronic swelling, pain, and skin changes after DVT) and pulmonary hypertension following a pulmonary embolism.
How Estrogen and Pregnancy Compound Clotting Risk
For women with factor V Leiden, estrogen is a major external risk factor that increases thrombotic tendencies.
When an asymptomatic woman with heterozygous factor V Leiden uses combined oral contraceptives (containing estrogen and progestin), her annual thrombosis risk increases to approximately 35 to 40 per 10,000 per year (around 0.5% annually)—a roughly 35-fold increase compared to non-carrier women not using oral contraceptives. Menopausal hormone replacement therapy (HRT) increases thrombotic risk roughly 15-fold in women with factor V Leiden compared to women not on HRT. Transdermal estrogen carries a lower thrombotic risk (hazard ratio 1.1) than oral estrogen formulations (hazard ratio 1.7).
Pregnancy increases DVT risk 5- to 8-fold in heterozygous factor V Leiden carriers compared to pregnant women without the mutation. In homozygous women, pregnancy-associated DVT risk increases 17- to 34-fold, with an absolute risk of 2.2% to 4.8% per pregnancy. The highest risk window occurs during the first six weeks postpartum. Additionally, factor V Leiden is associated with a 2- to 3-fold higher risk of recurrent miscarriages or late pregnancy loss during the second or third trimester.
Daily Life and Prevention: What Should You Avoid?
To reduce the risk of venous blood clots, clinical guidelines highlight several targeted precautions:
- Avoid combined estrogen medications: Women with factor V Leiden and a personal history of DVT, as well as homozygous carriers, should avoid estrogen-containing contraceptives and hormone replacement therapy. Asymptomatic heterozygous women should be counseled on the risks of estrogen-containing contraception and consider alternatives such as copper intrauterine devices (IUDs) or progestin-only methods. If oral contraceptives are chosen, third-generation progestins and other progestins associated with higher thrombotic risks should be avoided.
- Avoid prolonged immobility: Flights longer than 4 hours double the risk of venous thromboembolism; this risk peaks in the first week after travel and persists for up to 2 months. Graduated compression stockings (20–30 mmHg) are recommended for long-distance travelers with elevated risk. For travelers at very high risk, a prophylactic dose of low-molecular-weight heparin (such as 40 mg enoxaparin) before the flight and on the following day may be considered.
- Eliminate smoking: Tobacco smoking is an additional risk factor that should be minimized.
- Manage weight: Avoid obesity by maintaining a body mass index (BMI) under 30.
- Prepare for surgery: Homozygous factor V Leiden patients undergoing surgery are considered a high-risk group and should receive prophylactic anticoagulation. Heterozygous carriers not on long-term anticoagulation should undergo a risk-benefit assessment for short-term prophylaxis prior to surgery or pregnancy. Post-surgical measures recommended by the Mayo Clinic for carriers include short-term anticoagulation, pneumatic leg cuffs, compression stockings, and early ambulation.
Diagnosis and Treatment for Factor V Leiden
Factor V Leiden is diagnosed by molecular genetic detection of the c.1601G>A (p.Arg534Gln) variant in the F5 gene, performed either as a targeted test or through a multigene panel. A functional activated partial thromboplastin time (aPTT)-based APC resistance assay can serve as an initial screening test, with positive results confirmed by genetic testing. Genetic testing using polymerase chain reaction (PCR) and MnlI restriction digestion utilizes the fact that the mutation destroys an MnlI restriction enzyme cleavage site.
Genetic testing is recommended for individuals with DVT before age 50, thrombosis in unusual vascular sites, unprovoked or recurrent DVT, or a positive family history. Routine testing is not recommended for a first thrombosis occurring after age 50, prior to prescribing estrogen, during pregnancy, in asymptomatic children, or for prenatal diagnosis.
When factor V Leiden is identified, thrombophilia evaluation commonly includes screening for the prothrombin G20210A mutation, as well as measurements of protein C, protein S, and antithrombin.
Heterozygous individuals with factor V Leiden who have not had a thrombosis do not receive prophylactic anticoagulation, because the annual risk of bleeding on anticoagulants (1% to 3% per year) outweighs the annual clotting risk.
When an acute deep vein thrombosis or pulmonary embolism occurs, management follows standard venous thromboembolism protocols:
- Direct oral anticoagulants (DOACs: dabigatran, edoxaban, rivaroxaban, apixaban) are preferred over warfarin for initial therapy due to lower bleeding risk and greater convenience. The factor V Leiden mutation itself does not alter anticoagulant choice.
- The duration of anticoagulation is determined by whether the thrombosis was provoked or unprovoked, not by the mutation alone. A 2023 guideline recommends 3 to 6 months of anticoagulation following a first thrombosis in heterozygous carriers.
- Lifelong anticoagulation may be considered for homozygous factor V Leiden carriers or compound heterozygotes (factor V Leiden combined with the prothrombin mutation) when additional risk factors are present.
Common Myths and Misconceptions
- Myth: Factor V Leiden is a form of hemophilia or factor V deficiency. Factor V Leiden is a thrombophilia (hypercoagulable state) causing blood to clot more easily and faster. This is the opposite of hemophilia or factor deficiency disorders, where insufficient clotting causes bleeding.
- Myth: A positive test means you will inevitably get a blood clot. Around 95% of individuals with factor V Leiden never develop an abnormal blood clot during their lives. Carrying the mutation represents an increased risk, not a certainty.
- Myth: Factor V Leiden drastically reduces your life expectancy. Heterozygosity for factor V Leiden is not associated with increased overall mortality or reduced life expectancy, even after a previous DVT. A 1997 study of 171 parents of mutation carriers showed no increased mortality compared to the Dutch general population (standardized mortality ratio of 1.0). However, a 2026 real-world study of 241,572 factor V Leiden patients reported a significantly higher all-cause mortality (odds ratio 1.42), most pronounced in young women under 20 years of age (odds ratio 9.68). This 2026 finding challenges the classical consensus, indicating that current scientific evidence regarding mortality remains mixed.
- Myth: Everyone with a family member who has factor V Leiden needs routine genetic screening. The clinical indications for testing asymptomatic relatives remain controversial, and uniform guidelines are lacking. The American College of Medical Genetics and Genomics (ACMG) recommends testing first-degree relatives only when the test result would directly influence medical management. Routine screening is not recommended for asymptomatic children or prior to pregnancy or estrogen prescription, and testing should generally be delayed until adulthood so individuals can make their own informed decisions.
Frequently Asked Questions
Is Leiden factor 5 a blood disorder?
Factor V Leiden is not a blood disease in the sense of anemia or a factor deficiency. It is an inherited thrombophilia (a hypercoagulable state), where blood clots more easily and faster than normal because activated protein C inactivates factor V roughly ten times slower than normal.
What are the early signs of a blood clot in the neck?
An internal jugular vein thrombosis typically causes neck pain, swelling near the angle of the jaw, a sensation of pressure, a palpable cord running beneath the sternocleidomastoid muscle, and often headaches.
How does estrogen affect blood clots in factor V Leiden?
In women with heterozygous factor V Leiden, taking combined oral contraceptives increases annual clotting risk to 35 to 40 per 10,000 per year—an approximately 35-fold increase compared to non-carriers not on oral contraceptives. Hormone replacement therapy increases thrombosis risk roughly 15-fold.
What should you avoid with factor V Leiden?
Women with factor V Leiden and a prior DVT, as well as homozygous carriers, should avoid estrogen-containing contraceptives and hormone replacement therapy. Modifiable risk factors such as smoking, obesity (BMI > 30), and prolonged immobility should also be minimized.
Should family members get tested for factor V Leiden?
Routine screening of asymptomatic family members is not universally recommended. The ACMG advises testing first-degree relatives only if the result will alter clinical management. Routine testing is not recommended for asymptomatic children or prior to pregnancy or estrogen prescription, and testing is typically deferred until adulthood.